检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Michael B Atkins,Sandra J Lee,Bartosz Chmielowski,Ahmad A Tarhini,Gary I Cohen,Thach-Giao Truong,Helen H Moon,Diwakar Davar,Mark O'Rourke,Joseph J Stephenson,Brendan D Curti,Walter J Urba,Joanna M Brell,Pauline Funchain,Kari L Kendra,Alexandra P Ikeguchi,Anthony Jaslowski,Charles L Bane,Mark A Taylor,Madhuri Bajaj,Robert M Conry, Robert J Ellis,Theodore F Logan,Noel Laudi,Jeffrey A Sosman,David G Crockett,Andrew L Pecora,Ian J Okazaki,Sowjanya Reganti,Sunandana Chandra,Samantha Guild,Helen X Chen,Howard Z Streicher,Jedd D Wolchok,Antoni Ribas,John M Kirkwood

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 82|浏览47
暂无评分
摘要
Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要